Post-market Prospective Clinical Study of Nagor Perle Mammary Implants (PERLE10PMCF)

A Prospective, Multi-center, Observational, Non Comparative, Post-marketing Surveillance Study to Obtain Clinical Outcome Data on the Nagor PERLE Range of Silicone Breast Implants When Used in Breast Implantation

Patients can undergo breast implant surgery for multiple reasons; cosmetic and reconstructive being the primary indications. In order to confidently state safety and due to strict regulation on medical devices it is important to maintain a record of safety and performance with all medical implants.

This study is designed to collect data on a new generation of smooth mammary implants to assess the long term performance and safety data on this type of gel-filled mammary breast implant.

The two main complications of breast implants are capsular contracture and rupture; these complications can take years to develop. The study is designed to evaluate the occurrence of these two primary complication as well as other secondary complications over a period of 10 years. Patient follow up will be carried out pre-operatively and post operatively at 12 months and then 3, 5, 8 and 10 years thereafter.

The study will be carried out over 10 years to adequately assess complications which may only occur over the lifetime of the device such as systemic complications

Study Overview

• Status: Recruiting
• Conditions: Breast Augmentation; Breast Reconstruction; Breast Reconstruction Following Mastectomy; Breast Reconstruction Surgery; Breast Implants; Breast Revision; Breast Reconstruction With Silicone Implants; Breast Reconstruction After Mastectomy
• Intervention / Treatment: Device: PERLE Sterile Smooth Opaque gel filled mammary implants

• Study Type: Observational
• Enrollment (Estimated): 60

Contacts and Locations

• Study Contact: Name: Clinical Affairs Manager; Phone Number: +44 (0)1236 780780; Email: Perle10PMCF@gcaesthetics.com

Study Locations

• United Kingdom
  • Manchester, United Kingdom, M13 9WL
    • Recruiting
    • NHS Manchester
    • Principal Investigator: Nabila Nasir
    • Contact: Nasir N Principal Investigator; Phone Number: +44 (0)161 276 8686; Email: pals@mft.nhs.uk

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

Female 18-65 requiring breast surgery for iether augmentation, reconstruction or revision, meeting inclusion and non inclusion criteria

Description

Inclusion Criteria:

1. Genetic female subjects aged ≥18 and ≤65
2. Subjects who underwent single or bilateral breast implantation with the study device for one of the following reasons:-

i) Primary breast reconstruction following mastectomy (both for one-stage or two-stage surgeries, including patients with previous radiotherapy and who have ADMs of animal origin (bovine, porcine)). ii) Primary breast augmentation (cosmetic surgery) with or without mastopexy iii) Breast revision surgery with or without mastopexy c) Subjects who have received a Nagor PERLE implant. d) Subjects who have provided informed consent and can adhere to the requirements of follow up appointments as per the study protocol.

Exclusion Criteria:

1. Subjects undergoing implant augmentation with a BMI > 30 and undergoing reconstruction with a BMI >32.
2. Subjects with autoimmune disease, lung fibrocystic disease, conditions that interfere with wound healing and blood clotting, a weakened immune system, reduced blood supply to the breast tissue or any other condition for which breast implants are contraindicated.
3. Subjects who have participated in a clinical study which involve chemical or drug study within 3 months prior to surgery, with the exception of subjects who are participating in breast cancer related clinical studies.
4. Subjects with insufficient tissue covering due to either radiation damage on the chest wall, tight thoracic skin grafts or radical resection of the pectoralis major muscle.
5. Subjects who have ADMs of synthetic origin.
6. Subjects who, in the Investigator's clinical opinion, have existing local or metastatic carcinoma of the breast that is unlikely to be fully excised at the time of insertion of the breast implant.
7. Subjects with known previous history of a sensitivity to silicone who, in the opinion of the Investigator, are unsuitable for surgery.
8. Subjects with an active infection who are unsuitable for surgery unless, in the opinion of the investigator, they are treated and cleared by the investigator.
9. Subjects with a history of abscesses anywhere in the body who, in the opinion of the Investigator, are unsuitable for surgery.
10. Subjects with a known history of compromised wound healing.
11. Subjects who, in the opinion of the Investigator, have an existing condition that would compromise their participation and follow-up in this study.
12. Women who are pregnant and/or current breast feeders who do not stop breast feeding within 3 months of getting breast implants
13. Patients who have local recurrence or metastatic carcinoma at the time of insertion of breast implant

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort	Intervention / Treatment
Smooth Silicone Breast Implant	Device: PERLE Sterile Smooth Opaque gel filled mammary implants; Sterile smooth opaque gel filled mammary implants will be implanted in adult women having breast surgery for either augmentation, reconstruction or revision surgery. Different ranges of implants will be used to suit patient needs

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Rate of capsular contracture (Baker grade III-IV)	10 years post-surgery
Rate of implant rupture	10 years post-surgery

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Rate of the secondary surgical procedures required for correction of complications		10 years post-surgery
Rate and frequency of local complications associated with the use of Nagor gel-filled mammary implants	Capsular contracture of Baker Grade I-II; Haematoma; Rupture; Seroma; Severe and continuing pain; Post-operative infection; Explantation as a result of infection; Implant displacement/extrusion; Wrinkling/folds; Breast Implant Associate Anaplastic Large Cell Lymphoma; BII/Asia; Delayed or abnormal wound healing occurring within the first 3 months of surgery; Any other complications considered by the Investigator to be related to the device or surgical procedure	10 years post-surgery
Patient satisfaction	BREAST- Q method	10 years post-surgery
rate and frequency of any adverse events		10 years post-surgery

Collaborators and Investigators

• Sponsor: GC Aesthetics

Study record dates

Study Major Dates

• Study Start (Actual): June 1, 2024
• Primary Completion (Estimated): September 1, 2038
• Study Completion (Estimated): September 1, 2038

Study Registration Dates

• First Submitted: August 22, 2023
• First Submitted That Met QC Criteria: August 22, 2023
• First Posted (Actual): August 28, 2023

Study Record Updates

• Last Update Posted (Actual): July 11, 2025
• Last Update Submitted That Met QC Criteria: July 8, 2025
• Last Verified: July 1, 2025

More Information

Terms related to this study

• Keywords: prospective; observational; non-comparative; PMCF; GCA; post-marketing study; Perle; Nagor
• Other Study ID Numbers: DM6 640 0101

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No